-
10 Articoli
-
1 Foto
-
Video
-
Female
-
Seguito da 0 people
Aggiornamenti recenti
-
PIC/S GMP Annex 17 Explained: Parametric Release for Sterile Medicinal ProductsFor decades, proving the sterility of terminally sterilized pharmaceutical products relied on a traditional approach: standard finished product sterility testing. However, incubating sample units for 14 days can only confirm microbial contamination if it occurs in the test sample—it does not actively guarantee the sterility of the entire batch. Furthermore, traditional end-product testing...0 Commenti 0 condivisioni 1K Views 0 AnteprimaEffettua l'accesso per mettere mi piace, condividere e commentare!
-
PIC/S Inspection Readiness: How to Identify and Close GMP Compliance Gaps Before an Inspector ArrivesIn the global pharmaceutical marketplace, expanding into new international territories is essential for growth. However, navigating the varying regulatory expectations of multiple health authorities can quickly become an operational minefield. This is where the Pharmaceutical Inspection Co-operation Scheme (PIC/S) plays a transformative role. By harmonizing Good Manufacturing Practice (GMP)...0 Commenti 0 condivisioni 990 Views 0 Anteprima
-
PK-Stat Review for Clinical Trials: From Study Design to Regulatory-Ready PK DataIn modern drug development, generating clinical data is only half the battle. The true test of a successful trial lies in how rigorously that data is analyzed, interpreted, and presented to regulatory authorities. At the heart of pharmacokinetic and pharmacodynamic (PK/PD) evaluations are specialized PK-Stat (Pharmacokinetic-Statistical) reviews—a critical discipline that bridges clinical...0 Commenti 0 condivisioni 1K Views 0 Anteprima
-
Environmental Risk Assessment (ERA) Services in Europe: Supporting Pharmaceutical Companies with Regulatory ComplianceFor pharmaceutical companies seeking marketing authorization in Europe, proving safety and efficacy is only part of the equation. Today, every submission to the European Medicines Agency (EMA) or national competent authorities must also demonstrate that the medicinal product does not pose an unacceptable environmental risk. What was once viewed as a secondary regulatory checkbox has evolved...0 Commenti 0 condivisioni 1K Views 0 Anteprima
-
EU QPPV & Pharmacovigilance | ZenovelPatient safety does not end once a marketing authorization is secured. For any pharmaceutical company holding approvals in Europe, there is a continuous, legally binding duty to monitor, evaluate, and communicate the safety profile of their products. At the very center of this obligation stands the Qualified Person Responsible for Pharmacovigilance (QPPV). Far from being a mere administrative...0 Commenti 0 condivisioni 1K Views 0 Anteprima
-
Key Highlights of the NDCT Amendment Rules 2026: Transforming India’s Clinical Research LandscapeThe clinical research and pharmaceutical sectors in India are undergoing a profound evolution. To streamline drug development, eliminate procedural bottlenecks, and align national standards with global frameworks, the Ministry of Health and Family Welfare (MoHFW) and the Central Drugs Standard Control Organization (CDSCO) introduced the landmark New Drugs and Clinical Trials (NDCT) Amendment...0 Commenti 0 condivisioni 2K Views 0 Anteprima
-
Mastering Sponsor Oversight in Clinical Trials: Ensuring Quality and ComplianceIn modern clinical research, outsourcing operational tasks to Contract Research Organizations (CROs), vendors, and central laboratories is standard practice. However, there is one critical responsibility that a pharmaceutical or biotech sponsor can never outsource: sponsor oversight. Regulatory authorities worldwide—including the US FDA, EMA, and CDSCO—make it explicitly clear that...0 Commenti 0 condivisioni 2K Views 0 Anteprima
-
How Digital Technologies Are Transforming Clinical Trial Efficiency and ComplianceFor decades, traditional clinical trials have been hampered by high operational friction: slow patient recruitment, heavy administrative site burdens, static paper-based records, and data reconciliation bottlenecks. Today, the life sciences industry is experiencing a decisive shift. Digital technologies have moved past the initial experimentation phase, transforming into core infrastructure...0 Commenti 0 condivisioni 2K Views 0 Anteprima
-
Mastering PK-Stat Reviews in Bioequivalence Studies: Bridging Data and Regulatory SuccessIn the rigorous world of pharmaceutical development, proving that a generic or alternative formulation matches a brand-name reference product requires far more than just laboratory similarity. It demands undeniable mathematical and statistical proof. At the heart of this process lies the Pharmacokinetic-Statistical (PK-Stat) Review—the critical link that translates raw plasma...0 Commenti 0 condivisioni 2K Views 0 Anteprima
-
0 Commenti 0 condivisioni 715 Views 0 Anteprima
Altre storie